TABLE OF CONTENTS
|  | | | | Volume 32, Issue 2 (February 2018) |  | In this issue
 Perspective
Review
Original Articles
Letters to the Editor
Corrigenda
Also new
   AOP
| | | | | | Advertisement | | | | | | Perspective | Top | | Perspective on Diamond–Blackfan anemia: lessons from a rare congenital bone marrow failure syndrome OPEN K M Sakamoto and A Narla Leukemia 2018 32: 249-251; advance online publication, September 8, 2017; 10.1038/leu.2017.314 Full Text | | Review | Top | | Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond OPEN C S Chim, S K Kumar, R Z Orlowski, G Cook, P G Richardson, M A Gertz, S Giralt, M V Mateos, X Leleu and K C Anderson Leukemia 2018 32: 252-262; advance online publication, November 16, 2017; 10.1038/leu.2017.329 Abstract | Full Text | | Original Articles | Top | | ACUTE MYELOID LEUKEMIA | A four-gene LincRNA expression signature predicts risk in multiple cohorts of acute myeloid leukemia patients D Beck, J A I Thoms, C Palu, T Herold, A Shah, J Olivier, L Boelen, Y Huang, D Chacon, A Brown, M Babic, C Hahn, M Perugini, X Zhou, B J Huntly, A Schwarzer, J-H Klusmann, W E Berdel, B Wörmann, T Büchner, W Hiddemann, S K Bohlander, L B To, H S Scott, I D Lewis, R J D'Andrea, J W H Wong and J E Pimanda Leukemia 2018 32: 263-272; advance online publication, July 4, 2017; 10.1038/leu.2017.210 Abstract | Full Text | | | | The MLL recombinome of acute leukemias in 2017 OPEN C Meyer, T Burmeister, D Gröger, G Tsaur, L Fechina, A Renneville, R Sutton, N C Venn, M Emerenciano, M S Pombo-de-Oliveira, C Barbieri Blunck, B Almeida Lopes, J Zuna, J Trka, P Ballerini, H Lapillonne, M De Braekeleer, G Cazzaniga, L Corral Abascal, V H J van der Velden, E Delabesse, T S Park, S H Oh, M L M Silva, T Lund-Aho, V Juvonen, A S Moore, O Heidenreich, J Vormoor, E Zerkalenkova, Y Olshanskaya, C Bueno, P Menendez, A Teigler-Schlegel, U zur Stadt, J Lentes, G Göhring, A Kustanovich, O Aleinikova, B W Schäfer, S Kubetzko, H O Madsen, B Gruhn, X Duarte, P Gameiro, E Lippert, A Bidet, J M Cayuela, E Clappier, C N Alonso, C M Zwaan, M M van den Heuvel-Eibrink, S Izraeli, L Trakhtenbrot, P Archer, J Hancock, A Möricke, J Alten, M Schrappe, M Stanulla, S Strehl, A Attarbaschi, M Dworzak, O A Haas, R Panzer-Grümayer, L Sedék, T Szczepański, A Caye, L Suarez, H Cavé and R Marschalek Leukemia 2018 32: 273-284; advance online publication, July 13, 2017; 10.1038/leu.2017.213 Abstract | Full Text | | | | Retinoic acid and arsenic trioxide sensitize acute promyelocytic leukemia cells to ER stress OPEN S Masciarelli, E Capuano, T Ottone, M Divona, S De Panfilis, C Banella, N I Noguera, A Picardi, G Fontemaggi, G Blandino, F Lo-Coco and F Fazi Leukemia 2018 32: 285-294; advance online publication, August 4, 2017; 10.1038/leu.2017.231 Abstract | Full Text | | | | Number of RUNX1 mutations, wild-type allele loss and additional mutations impact on prognosis in adult RUNX1-mutated AML A Stengel, W Kern, M Meggendorfer, N Nadarajah, K Perglerovà, T Haferlach and C Haferlach Leukemia 2018 32: 295-302; advance online publication, July 28, 2017; 10.1038/leu.2017.239 Abstract | Full Text | | | | Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1 T-C Teh, N-Y Nguyen, D M Moujalled, D Segal, G Pomilio, S Rijal, A Jabbour, K Cummins, K Lackovic, P Blombery, E Thompson, P G Ekert, G Lessene, S P Glaser, D C S Huang, A W Roberts, M A Guthridge and A H Wei Leukemia 2018 32: 303-312; advance online publication, July 28, 2017; 10.1038/leu.2017.243 Abstract | Full Text | | | | Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia OPEN K Reiter, H Polzer, C Krupka, A Maiser, B Vick, M Rothenberg-Thurley, K H Metzeler, D Dörfel, H R Salih, G Jung, E Nößner, I Jeremias, W Hiddemann, H Leonhardt, K Spiekermann, M Subklewe and P A Greif Leukemia 2018 32: 313-322; advance online publication, August 14, 2017; 10.1038/leu.2017.257 Abstract | Full Text | | | | ACUTE LYMPHOBLASTIC LEUKEMIA | The HDAC inhibitor panobinostat (LBH589) exerts in vivo anti-leukaemic activity against MLL-rearranged acute lymphoblastic leukaemia and involves the RNF20/RNF40/WAC-H2B ubiquitination axis P Garrido Castro, E H J van Roon, S S Pinhanços, L Trentin, P Schneider, M Kerstjens, G te Kronnie, O Heidenreich, R Pieters and R W Stam Leukemia 2018 32: 323-331; advance online publication, July 10, 2017; 10.1038/leu.2017.216 Abstract | Full Text | | | | CHRONIC LYMPHOCYTIC LEUKEMIA | Whole-genome sequencing of chronic lymphocytic leukaemia reveals distinct differences in the mutational landscape between IgHVmut and IgHVunmut subgroups OPEN A Burns, R Alsolami, J Becq, B Stamatopoulos, A Timbs, D Bruce, P Robbe, D Vavoulis, R Clifford, M Cabes, H Dreau, J Taylor, S J L Knight, R Mansson, D Bentley, R Beekman, J I Martín-Subero, E Campo, R S Houlston, K E Ridout and A Schuh Leukemia 2018 32: 332-342; advance online publication, June 6, 2017; 10.1038/leu.2017.177 Abstract | Full Text | | | | LYMPHOMA | BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells B Sun, W Fiskus, Y Qian, K Rajapakshe, K Raina, K G Coleman, A P Crew, A Shen, D T Saenz, C P Mill, A J Nowak, N Jain, L Zhang, M Wang, J D Khoury, C Coarfa, C M Crews and K N Bhalla Leukemia 2018 32: 343-352; advance online publication, June 30, 2017; 10.1038/leu.2017.207 Abstract | Full Text | | | | Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy Z Yao, L Deng, Z Y Xu-Monette, G C Manyam, P Jain, A Tzankov, C Visco, G Bhagat, J Wang, K Dybkaer, W Tam, E D Hsi, J H van Krieken, M Ponzoni, A J M Ferreri, M B Møller, J N Winter, M A Piris, L Fayad, Y Liu, Y Song, R Z Orlowski, H Kantarjian, L J Medeiros, Y Li, J Cortes and K H Young Leukemia 2018 32: 353-363; advance online publication, July 12, 2017; 10.1038/leu.2017.222 Abstract | Full Text | | | | Lamin B1 regulates somatic mutations and progression of B-cell malignancies OPEN T Klymenko, J Bloehdorn, J Bahlo, S Robrecht, G Akylzhanova, K Cox, S Estenfelder, J Wang, J Edelmann, J C Strefford, T K Wojdacz, K Fischer, M Hallek, S Stilgenbauer, M Cragg, J Gribben and A Braun Leukemia 2018 32: 364-375; advance online publication, August 14, 2017; 10.1038/leu.2017.255 Abstract | Full Text | | | | MULTIPLE MYELOMA, GAMMOPATHIES | Heavy+light chain monitoring correlates with clinical outcome in multiple myeloma patients OPEN M Michallet, C Chapuis-Cellier, T Dejoie, C Lombard, H Caillon, M Sobh, P Moreau, M Attal and H Avet-Loiseau Leukemia 2018 32: 376-382; advance online publication, June 30, 2017; 10.1038/leu.2017.209 Abstract | Full Text | | | | Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial H Goldschmidt, H M Lokhorst, E K Mai, B van der Holt, I W Blau, S Zweegman, K C Weisel, E Vellenga, M Pfreundschuh, M J Kersten, C Scheid, S Croockewit, R Raymakers, D Hose, A Potamianou, A Jauch, J Hillengass, M Stevens-Kroef, M S Raab, A Broijl, H W Lindemann, G M J Bos, P Brossart, M van Marwijk Kooy, P Ypma, U Duehrsen, R M Schaafsma, U Bertsch, T Hielscher, Le Jarari, H J Salwender and P Sonneveld Leukemia 2018 32: 383-390; advance online publication, July 4, 2017; 10.1038/leu.2017.211 Abstract | Full Text | | | | Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma OPEN A Besse, S C Stolze, L Rasche, N Weinhold, G J Morgan, M Kraus, J Bader, H S Overkleeft, L Besse and C Driessen Leukemia 2018 32: 391-401; advance online publication, July 5, 2017; 10.1038/leu.2017.212 Abstract | Full Text | | | | A compound chimeric antigen receptor strategy for targeting multiple myeloma OPEN K H Chen, M Wada, K G Pinz, H Liu, X Shuai, X Chen, L E Yan, J C Petrov, H Salman, L Senzel, E L H Leung, X Jiang and Y Ma Leukemia 2018 32: 402-412; advance online publication, September 27, 2017; 10.1038/leu.2017.302 Abstract | Full Text | | | | MYELODYSPLASTIC SYNDROME | A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia OPEN V Santini, B Allione, G Zini, D Gioia, M Lunghi, A Poloni, D Cilloni, A Sanna, E Masiera, M Ceccarelli, O Abdel-Wahab, A Terenzi, E Angelucci, C Finelli, F Onida, A Pelizzari, D Ferrero, G Saglio, M Figueroa and A Levis Leukemia 2018 32: 413-418; advance online publication, June 13, 2017; 10.1038/leu.2017.186 Abstract | Full Text | | | | High expression of ABCG2 induced by EZH2 disruption has pivotal roles in MDS pathogenesis K C Kawabata, Y Hayashi, D Inoue, H Meguro, H Sakurai, T Fukuyama, Y Tanaka, S Asada, T Fukushima, R Nagase, R Takeda, Y Harada, J Kitaura, S Goyama, H Harada, H Aburatani and T Kitamura Leukemia 2018 32: 419-428; advance online publication, July 19, 2017; 10.1038/leu.2017.227 Abstract | Full Text | | | | CHRONIC MYELOPROLIFERATIVE NEOPLASMS | The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy M O Holmström, E Martinenaite, S M Ahmad, Ö Met, C Friese, L Kjær, C H Riley, P thor Straten, I M Svane, H C Hasselbalch and M H Andersen Leukemia 2018 32: 429-437; advance online publication, July 5, 2017; 10.1038/leu.2017.214 Abstract | Full Text | | | | Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients OPEN S Ruberti, E Bianchi, P Guglielmelli, S Rontauroli, G Barbieri, L Tavernari, T Fanelli, R Norfo, V Pennucci, G Corbizi Fattori, C Mannarelli, N Bartalucci, B Mora, L Elli, M A Avanzini, C Rossi, S Salmoiraghi, R Zini, S Salati, Z Prudente, V Rosti, F Passamonti, A Rambaldi, S Ferrari, E Tagliafico, A M Vannucchi and R Manfredini on behalf of the AGIMM (AIRC Gruppo Italiano Malattie Mieloproliferative) Investigators Leukemia 2018 32: 438-449; advance online publication, July 12, 2017; 10.1038/leu.2017.220 Abstract | Full Text | | | | Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status OPEN B Kubesova, S Pavlova, J Malcikova, J Kabathova, L Radova, N Tom, B Tichy, K Plevova, B Kantorova, K Fiedorova, M Slavikova, V Bystry, J Kissova, B Gisslinger, H Gisslinger, M Penka, J Mayer, R Kralovics, S Pospisilova and M Doubek Leukemia 2018 32: 450-461; advance online publication, July 24, 2017; 10.1038/leu.2017.230 Abstract | Full Text | | | | The JAK2V617F-bearing vascular niche promotes clonal expansion in myeloproliferative neoplasms OPEN H Zhan, C H S Lin, Y Segal and K Kaushansky Leukemia 2018 32: 462-469; advance online publication, July 24, 2017; 10.1038/leu.2017.233 Abstract | Full Text | | | | Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial D J DeAngelo, T I George, A Linder, C Langford, C Perkins, J Ma, P Westervelt, J D Merker, C Berube, S Coutre, M Liedtke, B Medeiros, D Sternberg, C Dutreix, P-A Ruffie, C Corless, T J Graubert and J Gotlib Leukemia 2018 32: 470-478; advance online publication, July 24, 2017; 10.1038/leu.2017.234 Abstract | Full Text | | | | STEM CELL BIOLOGY | Transforming growth factor-β1 regulates the nascent hematopoietic stem cell niche by promoting gluconeogenesis C-Y Zhang, H-M Yin, H Wang, D Su, Y Xia, L-F Yan, B Fang, W Liu, Y-M Wang, A-H Gu and Y Zhou Leukemia 2018 32: 479-491; advance online publication, June 23, 2017; 10.1038/leu.2017.198 Abstract | Full Text | | | | STEM CELL TRANSPLANTATION | Donor and recipient age, gender and ABO incompatibility regardless of donor source: validated criteria for donor selection for haematopoietic transplants Y Wang, D-P Wu, Q-F Liu, L-P Xu, K-Y Liu, X-H Zhang, Y Xu, F Huang and X-J Huang Leukemia 2018 32: 492-498; advance online publication, June 23, 2017; 10.1038/leu.2017.199 Abstract | Full Text | | | | MOLECULAR TARGETS FOR THERAPY | Genetic deletion or small-molecule inhibition of the arginine methyltransferase PRMT5 exhibit anti-tumoral activity in mouse models of MLL-rearranged AML S Kaushik, F Liu, K J Veazey, G Gao, P Das, L F Neves, K Lin, Y Zhong, Y Lu, V Giuliani, M T Bedford, S D Nimer and M A Santos Leukemia 2018 32: 499-509; advance online publication, June 30, 2017; 10.1038/leu.2017.206 Abstract | Full Text | | | | An atlas of bloodstream-accessible bone marrow proteins for site-directed therapy of acute myeloid leukemia L Angenendt, S Reuter, D Kentrup, A S Benk, F Neumann, J Hüve, A C Martens, C Schwöppe, T Kessler, L H Schmidt, T Sauer, C Brand, J-H Mikesch, G Lenz, R M Mesters, C Müller-Tidow, W Hartmann, E Wardelmann, D Neri, W E Berdel, C Roesli and C Schliemann Leukemia 2018 32: 510-519; advance online publication, June 30, 2017; 10.1038/leu.2017.208 Abstract | Full Text | | | | IMMUNOTHERAPY | Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity E Liu, Y Tong, G Dotti, H Shaim, B Savoldo, M Mukherjee, J Orange, X Wan, X Lu, A Reynolds, M Gagea, P Banerjee, R Cai, M H Bdaiwi, R Basar, M Muftuoglu, L Li, D Marin, W Wierda, M Keating, R Champlin, E Shpall and K Rezvani Leukemia 2018 32: 520-531; advance online publication, July 20, 2017; 10.1038/leu.2017.226 Abstract | Full Text | | | | CYTOGENETICS AND MOLECULAR GENETICS | Intrapatient functional clonality deconvoluted by coupling intracellular flow cytometry and next-generation sequencing in human leukemia Q Zhang, M C Ball, Y Zhao, M Balasis, C Letson, A Vedder, A F List, P K Epling-Burnette, R S Komrokji and E Padron Leukemia 2018 32: 532-538; advance online publication, June 21, 2017; 10.1038/leu.2017.184 Abstract | Full Text | | Letters to the Editor | Top | | Generation of a multi-antigen-directed immune response for durable control of acute lymphoblastic leukemia S Jo, J H Lee, J J Mattei, D M Barrett, P van den Elzen, S A Grupp, G S D Reid and A E Seif Leukemia 2018 32: 539-542; advance online publication, September 19, 2017; 10.1038/leu.2017.290 Full Text | | | | Refined karyotype-based prognostic stratification of chronic lymphocytic leukemia with a low- and very-low-risk genetic profile I Del Giudice, G M Rigolin, S Raponi, L Cafforio, C Ilari, J Wang, M Bordyuh, A Piciocchi, M Marinelli, M Nanni, S Tavolaro, M Filetti, A Bardi, E Tammiso, E Volta, M Negrini, E Saccenti, F R Mauro, D Rossi, G Gaidano, A Guarini, R Rabadan, A Cuneo and R Foà Leukemia 2018 32: 543-546; advance online publication, September 19, 2017; 10.1038/leu.2017.292 Full Text | | | | A new mouse expressing human Fcγ receptors to better predict therapeutic efficacy of human anti-cancer antibodies E Casey, S Bournazos, G Mo, P Mondello, K S Tan, J V Ravetch and D A Scheinberg Leukemia 2018 32: 547-549; advance online publication, September 19, 2017; 10.1038/leu.2017.293 Full Text | | | | Distinct clinical and biological implications of various DNMT3A mutations in myeloid neoplasms S K Balasubramanian, M Aly, Y Nagata, T Bat, B P Przychodzen, C M Hirsch, V Adema, V Visconte, T Kuzmanovic, T Radivoyevitch, A Nazha, S Mukherjee, M A Sekeres and J P Maciejewski Leukemia 2018 32: 550-553; advance online publication, September 22, 2017; 10.1038/leu.2017.295 Full Text | | | | Performance of the myelofibrosis secondary to PV and ET-prognostic model (MYSEC-PM) in a series of 262 patients from the Spanish registry of myelofibrosis J-C Hernández-Boluda, A Pereira, J-G Correa, A Alvarez-Larrán, F Ferrer-Marín, J-M Raya, J Martínez-López, M Pérez-Encinas, N Estrada, P Velez, M-L Fox, V García-Gutiérrez, A Payer, A Kerguelen, B Cuevas, M-A Durán, M-J Ramírez, M-T Gómez-Casares, M-I Mata-Vázquez, E Mora, C Martínez-Valverde, M Gómez and F Cervantes on behalf of the Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN) Leukemia 2018 32: 553-555; advance online publication, September 22, 2017; 10.1038/leu.2017.297 Full Text | | | | Fibrotic progression in Polycythemia vera is associated with early concomitant driver-mutations besides JAK2 S Bartels, M Faisal, G Büsche, J Schlue, H Kreipe and U Lehmann Leukemia 2018 32: 556-558; advance online publication, September 22, 2017; 10.1038/leu.2017.298 Full Text | | | | Lenalidomide-mediated erythroid improvement in non-del(5q) myelodysplastic syndromes is associated with bone marrow immuno-remodeling G Kerdivel, V Chesnais, E Becht, A Toma, N Cagnard, F Dumont, A Rousseau, P Fenaux, S Chevret, N Chapuis, V Boeva, W H Fridman, M Fontenay and O Kosmider on behalf of the Groupe Francophone des Myélodysplasies Leukemia 2018 32: 558-562; advance online publication, October 3, 2017; 10.1038/leu.2017.305 Full Text | | | | Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia OPEN M S Topp, M Stelljes, G Zugmaier, P Barnette, L T Heffner, Jr, T Trippett, J Duell, R C Bargou, C Holland, J E Benjamin, M Klinger and M R Litzow Leukemia 2018 32: 562-565; advance online publication, October 9, 2017; 10.1038/leu.2017.306 Full Text | | | | Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma G Hu, S Dasari, Y W Asmann, P T Greipp, R A Knudson, H K Benson, Y Li, B W Eckloff, J Jen, B K Link, L Jiang, J S Sidhu, L E Wellik, T E Witzig, N N Bennani, J R Cerhan, R L Boddicker and A L Feldman Leukemia 2018 32: 565-569; advance online publication, October 13, 2017; 10.1038/leu.2017.309 Full Text | | | | Recombinant immunotoxins targeting B-cell maturation antigen are cytotoxic to myeloma cell lines and myeloma cells from patients OPEN T K Bera, Y Abe, T Ise, A Oberle, D Gallardo, X-f Liu, S Nagata, M Binder and I Pastan Leukemia 2018 32: 569-572; advance online publication, November 17, 2017; 10.1038/leu.2017.315 Full Text | | Corrigenda | Top | | miR-194-5p/BCLAF1 deregulation in AML tumorigenesis C Dell'Aversana, C Giorgio, L D'Amato, G Lania, F Matarese, S Saeed, A Di Costanzo, V Belsito Petrizzi, C Ingenito, J H A Martens, I Pallavicini, S Minucci, A Carissimo, H G Stunnenberg and L Altucci Leukemia 2018 32: 573; advance online publication, December 22, 2017; 10.1038/leu.2017.310 Full Text | | | | Whole-genome sequencing of chronic lymphocytic leukaemia reveals distinct differences in the mutational landscape between IgHVmut and IgHVunmut subgroups OPEN A Burns, R Alsolami, J Becq, B Stamatopoulos, A Timbs, D Bruce, P Robbe, D Vavoulis, R Clifford, M Cabes, H Dreau, J Taylor, S J L Knight, R Mansson, D Bentley, R Beekman, J I Martín-Subero, E Campo, R S Houlston, K E Ridout and A Schuh Leukemia 2018 32: 573; advance online publication, November 21, 2017; 10.1038/leu.2017.311 Full Text | | | | Generation of a multi-antigen-directed immune response for durable control of acute lymphoblastic leukemia S Jo, J H Lee, J J Mattei, D M Barrett, P van den Elzen, S A Grupp, G S D Reid and A E Seif Leukemia 2018 32: 574; advance online publication, January 5, 2018; 10.1038/leu.2017.312 Full Text | | | | Proteomic analysis of JAK2V617F-induced changes identifies potential new combinatorial therapeutic approaches OPEN S Pearson, A J K Williamson, R Blance, T C P Somervaille, S Taylor, N Azadbakht, A D Whetton and A Pierce Leukemia 2018 32: 574; advance online publication, December 19, 2017; 10.1038/leu.2017.333 Full Text | | | | |  | | | | | | Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.
Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com | | | | | | | | | Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Leukemia. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Springer Nature |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Springer Nature's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2018 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved. |  | | | | |
No comments:
Post a Comment